Overt

OverT Bio is a clinical-stage biotechnology company developing next-generation, programmed off-the-shelf (allogeneic) cell therapies and biologics for solid tumors. The company pairs AI-powered genome-scale genetic discovery with tumor-targeting receptor engineering and naturally tumor-homing gamma delta T cells, plus scalable manufacturing intended to reduce treatment time and cost. Its pipeline includes OVT-101, a CLDN6-targeted CAR-T for ovarian cancer (first-in-human anticipated H1 2027), and OVT-201, a non-MHC T cell engager for solid tumors. Based in New York City and backed by Wing Venture Capital. As a therapeutics company, OverT Bio publishes no public API, developer portal, SDKs, or machine-readable specifications.

Overt is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Cell Therapy, Immunotherapy, and Oncology.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotechnologyCell TherapyImmunotherapyOncologyLife SciencesDrug DiscoveryArtificial Intelligence

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/overt: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Resources

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: overt
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/overt.png
name: Overt
description: OverT Bio is a clinical-stage biotechnology company developing next-generation, programmed off-the-shelf (allogeneic)
  cell therapies and biologics for solid tumors. The company pairs AI-powered genome-scale genetic discovery with tumor-targeting
  receptor engineering and naturally tumor-homing gamma delta T cells, plus scalable manufacturing intended to reduce treatment
  time and cost. Its pipeline includes OVT-101, a CLDN6-targeted CAR-T for ovarian cancer (first-in-human anticipated H1 2027),
  and OVT-201, a non-MHC T cell engager for solid tumors. Based in New York City and backed by Wing Venture Capital. As a
  therapeutics company, OverT Bio publishes no public API, developer portal, SDKs, or machine-readable specifications.
url: https://raw.githubusercontent.com/api-evangelist/overt/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- wing-venture-capital
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-20'
tags:
- Company
- Biotechnology
- Cell Therapy
- Immunotherapy
- Oncology
- Life Sciences
- Drug Discovery
- Artificial Intelligence
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.overt.bio/
x-enrichment:
  date: '2026-07-20'
  status: nochange
  artifacts_added: 0
  pass: local-v1